NASDAQ:PRAX Praxis Precision Medicines (PRAX) Stock Price, News & Analysis $57.69 +0.15 (+0.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$57.47▼$59.4850-Day Range$36.55▼$58.2152-Week Range$12.75▼$67.21Volume145,608 shsAverage Volume284,143 shsMarket Capitalization$987.08 millionP/E RatioN/ADividend YieldN/APrice Target$137.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Praxis Precision Medicines alerts: Email Address Praxis Precision Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside138.1% Upside$137.38 Price TargetShort InterestBearish10.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($10.13) to ($9.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.66 out of 5 starsMedical Sector487th out of 936 stocksPharmaceutical Preparations Industry225th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingPraxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePraxis Precision Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Praxis Precision Medicines' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.39% of the float of Praxis Precision Medicines has been sold short.Short Interest Ratio / Days to CoverPraxis Precision Medicines has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Praxis Precision Medicines has recently increased by 12.77%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPraxis Precision Medicines does not currently pay a dividend.Dividend GrowthPraxis Precision Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRAX. Previous Next 2.3 News and Social Media Coverage News SentimentPraxis Precision Medicines has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Praxis Precision Medicines this week, compared to 3 articles on an average week.Search Interest10 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.70% of the stock of Praxis Precision Medicines is held by insiders.Percentage Held by Institutions67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Praxis Precision Medicines' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Praxis Precision Medicines are expected to grow in the coming year, from ($10.13) to ($9.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Praxis Precision Medicines is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Praxis Precision Medicines is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPraxis Precision Medicines has a P/B Ratio of 7.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Praxis Precision Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Praxis Precision Medicines Stock (NASDAQ:PRAX)Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Read More PRAX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRAX Stock News HeadlinesJuly 25 at 10:17 PM | finance.yahoo.comPRAX Aug 2024 50.000 put (PRAX240816P00050000)July 24 at 1:46 PM | msn.comSage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug FailsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 24 at 8:45 AM | msn.comExperts unveil first comprehensive guidelines for precision medicine researchJuly 24 at 8:45 AM | msn.comNew guideline to improve reporting in precision medicine globallyJuly 22, 2024 | msn.comUVA advances precision medicine to defeat breast cancer with Komen grantJuly 16, 2024 | americanbankingnews.comAnalysts Set Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Price Target at $137.38June 4, 2024 | globenewswire.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 23, 2024 | uk.investing.comPraxis Precision Medicines shares maintain price targetMay 22, 2024 | msn.comPraxis Precision Medicines (NASDAQ:PRAX): A Wild Rollercoaster RideMay 17, 2024 | globenewswire.comPraxis Precision Medicines to Participate in Upcoming Investor ConferencesMay 16, 2024 | markets.businessinsider.comCritical Insights From Praxis Precision Medicine Analyst Ratings: What You Need To KnowMay 16, 2024 | markets.businessinsider.comBuy Rating Backed by Robust Pipeline and Market Opportunity for Praxis Precision MedicinesMay 14, 2024 | finance.yahoo.comWe're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash WiselyMay 13, 2024 | marketwatch.comPraxis Precision Medicines Shares Drop 5% After 1Q Results Miss ExpectationsMay 13, 2024 | finanznachrichten.dePraxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | msn.comPraxis Precision Medicines GAAP EPS of -$2.84 misses by $0.75, revenue of $0.43M misses by $1.33MSee More Headlines Receive PRAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRAX CUSIPN/A CIK1689548 Webwww.praxismedicines.com Phone617-300-8460FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$137.38 High Stock Price Target$270.00 Low Stock Price Target$29.00 Potential Upside/Downside+138.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($15.8550) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,280,000.00 Net Margins-5,711.85% Pretax Margin-5,711.85% Return on Equity-101.99% Return on Assets-86.68% Debt Debt-to-Equity RatioN/A Current Ratio11.27 Quick Ratio11.27 Sales & Book Value Annual Sales$2.45 million Price / Sales402.89 Cash FlowN/A Price / Cash FlowN/A Book Value$7.92 per share Price / Book7.28Miscellaneous Outstanding Shares17,110,000Free Float16,646,000Market Cap$987.08 million OptionableOptionable Beta2.74 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Marcio Silva De'Souza M.B.A. (Age 45)President, CEO & Director Comp: $1.18MMr. Timothy Edwin Kelly (Age 50)CFO & Treasurer Comp: $691.58kMr. Alex Nemiroff J.D. (Age 44)General Counsel & Secretary Comp: $577.34kDr. Steven Petrou B.Sc. (Hons.)Ph.D., Co-Founder & Chief Scientific OfficerLauren MastrocolaVP of Finance & Principal Accounting OfficerDr. Karl Hansen Ph.D.Chief Technical Operations OfficerAlex KaneVP of Investor Relations & Corporate CommunicationsMs. Kelly McCueChief People OfficerMs. Alyssa J. S. Wyant (Age 49)Chief Regulatory & Quality Officer Ms. Megan T. Sniecinski (Age 42)Chief Business Officer More ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTTravere TherapeuticsNASDAQ:TVTXSage TherapeuticsNASDAQ:SAGECOMPASS PathwaysNASDAQ:CMPSMacroGenicsNASDAQ:MGNXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 49,510 shares on 7/26/2024Ownership: 0.289%Assenagon Asset Management S.A.Sold 51,492 shares on 7/18/2024Ownership: 0.115%PCG Wealth Advisors LLCBought 4,524 shares on 7/16/2024Ownership: 0.102%Farallon Capital Management LLCBought 50,000 shares on 5/24/2024Ownership: 0.292%RA Capital Management L.P.Bought 828,380 shares on 5/17/2024Ownership: 4.841%View All Insider TransactionsView All Institutional Transactions PRAX Stock Analysis - Frequently Asked Questions How have PRAX shares performed this year? Praxis Precision Medicines' stock was trading at $22.28 at the beginning of 2024. Since then, PRAX stock has increased by 158.9% and is now trading at $57.69. View the best growth stocks for 2024 here. How were Praxis Precision Medicines' earnings last quarter? Praxis Precision Medicines, Inc. (NASDAQ:PRAX) issued its earnings results on Monday, May, 13th. The company reported ($2.84) EPS for the quarter, missing analysts' consensus estimates of ($2.01) by $0.83. The firm earned $0.43 million during the quarter, compared to analysts' expectations of $2.75 million. Praxis Precision Medicines had a negative net margin of 5,711.85% and a negative trailing twelve-month return on equity of 101.99%. When did Praxis Precision Medicines' stock split? Shares of Praxis Precision Medicines reverse split on the morning of Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Praxis Precision Medicines IPO? Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager. Who are Praxis Precision Medicines' major shareholders? Top institutional shareholders of Praxis Precision Medicines include Bank of New York Mellon Corp (0.29%), Assenagon Asset Management S.A. (0.12%) and PCG Wealth Advisors LLC (0.10%). Insiders that own company stock include Dean J Mitchell, Marcio Souza, Timothy Edwin Kelly, Alex Nemiroff, Lauren Mastrocola, Jill Desimone and Parallel Master Fund LP Bsof. View institutional ownership trends. How do I buy shares of Praxis Precision Medicines? Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRAX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.